Format

Send to

Choose Destination
ACS Chem Neurosci. 2014 Dec 17;5(12):1146-7. doi: 10.1021/cn500285h. Epub 2014 Nov 18.

Are we using the right pharmacological tools to target EphA4?

Author information

1
Dipartimento di Farmacia, Università di Parma , Viale delle Scienze 27/a, 43124 Parma, Italia.

Abstract

The EphA4 receptor has been proposed to be a key actor in neurodegenerative diseases. In the last years, several research groups focused their efforts on the discovery of small molecules capable of blocking EphA4 activity by binding its extracellular domain. However, none of the compounds so far identified possess adequate chemical and/or pharmacological profiles to assess the "druggability" of EphA4 in animal models. New efforts are required to deliver a new generation of suitable pharmacological tools.

KEYWORDS:

Eph-ephrin antagonist; EphA4; Rhynchophylline; UniPR129; compound 1

PMID:
25405504
DOI:
10.1021/cn500285h
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for American Chemical Society
Loading ...
Support Center